TP53 and serous adenocarcinoma: Moreover, approximately 90% of all patients with serous epithelial ovarian cancer have a TP53 variant.14 We found a TP53 variant in 59% of patients, which might be explained by tumor heterogeneity.24 Also, three of our five patients without a pathogenic variant in the surgical specimen had a high-grade serous carcinoma.